Keep REMS ed optional: AAFP

At an FDA public meeting on issues and challenges around risk evaluation and mitigation strategy (REMS), the AAFP urged the agency to keep REMS-specific CME for extended-release and long-acting opioids voluntary, reported AAFP News Now.

Ann Karty, MD, medical director of the AAFP division of CME, said a prescriber-education mandate could impact patient access to those drugs.

It could also create confusion for doctors who are licensed in multiple states.

“If you start adding more requirements… there is the potential that some will not participate,” Karty told AAFP News Now.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.